Receiving double recognition at the AREA | Takeda Philippines

Takeda Philippines Healthcare, Inc. (“Takeda”), a leading pharmaceutical company committed to create better health for people and a brighter future for the world, has been recognized with two prestigious awards at the Asia Responsible Enterprise Awards (AREA) ceremony held in Cambodia.

The first award was given to Takeda's Access To Medicines: Patient Assistance Program (AtM Program) in the Health Promotion category. Rooted in the vision of broadening access to life-changing medicines and vaccines in underserved communities, the AtM Program utilizes an integrated and sustainable approach that mobilizes the collective efforts of all involved stakeholders.

Focusing on diseases with the highest unmet need such as cancer and rare diseases, Takeda strives to bring its innovative and high-quality medicines to patients in the Philippines who have limited access to healthcare services. Through this program, the company has successfully provided financial assistance to over 600 patients nationwide, ensuring they receive crucial treatments regardless of their capacity to pay.

The AtM Program involves multi-stakeholder collaboration to address the pain points in the patient’s journey in the areas of disease awareness, accurate diagnosis, and appropriate treatment, support, and care. Based on Takeda’s insights on Filipino patients, it takes them about 5 to 10 visits to different doctors before they are properly diagnosed. Thus, the “Spot Lymphoma, Stop Lymphoma” campaign was launched together with 5 major medical societies and 2 non-government organizations to educate patients. Takeda in partnership with Philippine Cancer Society (PCS) provided CD30 screening through 24 hospitals majority of which are located outside of the capital of Metro Manila so patients would have access to CD30 screening.

Aside from screening, a series of workshops with Philippine Pathologists in partnership with medical societies were done to increase the skills and confidence of pathologists in utilizing immunohistochemistry and ensure early and proper diagnosis. The cornerstone of Takeda’s access program in the country is the Patient Assistance Program (PAP). This unique and innovative affordability-based program enabled more than 600 patients regardless of their socio-economic class to access their treatment with Takeda’s target therapy at a price that is based on the patient’s financial capacity to pay.

Takeda also partnered with an NGO to provide a series of training to oncology nurses to enrich their capability in educating patients. They also provided a grant to the Cancer Care Registry and Research Philippines Foundation (CARE PH) to expand its cancer registry and research. Finally, as a culmination of Takeda’s holistic initiatives in 2022, the Access to Medicines (ATM) Summit gathered 137 multi-sectoral stakeholders from 42 organizations for a 2-day meeting, and discussed how each can support healthcare strengthening in the Philippines. Takeda’s framework is to build sustainable capacity at every stage from diagnosis to ongoing patient support. To date, more than 1,700 pathologists, 6,997 oncology and 5,683 endoscopy nurses, 4 medical societies, and 7 NGOs and patient organizations have partnered with Takeda in these endeavors.

The second award recognized Takeda for its unwavering dedication to employee well-being and engagement in the Investment in People category. These programs aim to foster a healthy and collaborative working environment, enabling employees to thrive personally and professionally.

Takeda's employee well-being and engagement programs encompass diverse wellness initiatives and engagement activities that encourage a robust and motivated workforce. From the Partnerships for Growth (PFG) mentoring program, Lunch and Learn sessions, to career development and energy management workshops, Takeda invests in its employees' growth and development. These engagement efforts cultivate open communication, collaborative relationships, and contribute to the company's talent development and retention strategies, resulting in sustained high engagement levels with an average of 92% in the last two years of the company’s annual engagement survey.

Takeda's dedication to its employees has also led to the prestigious Great Place to Work® certification for two consecutive years, as well as one of 2023 Philippines Best Workplaces. The company remains steadfast in ensuring its programs cater to the needs of its workforce, empowering them to flourish and reach their full potential.

"We are honored to receive these recognitions as it cements Takeda’s enduring commitment to serve communities as well as our employees," Loreann Villanueva, Country Manager of Takeda Healthcare Philippines Inc. said. "These awards inspire us to push the boundaries further, making a lasting difference to the Filipino community through an empowered and highly dedicated workforce."

AREA recognizes and honors deserving Asian businesses for championing sustainable and responsible business practices in the following categories: Green Leadership, Social Empowerment, Health Promotion, Investment in People, Corporate Governance, Circular Economy Leadership, Corporate Sustainability Reporting and Responsible Business Leadership.

About Takeda

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

About Takeda Philippines

Takeda Healthcare Philippines, Inc. (THPI) is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. Founded in 1968, THPI aims to broaden patient access to treatment across the country through sustainable access programs enabling affordable and integrated access solutions for disease areas such as oncology, gastroenterology, rare diseases & vaccines and by strengthening the healthcare system guided by our commitment to Patients, our People and the Planet.

For more information, visit https://www.takeda.com.

Media Contacts:

Takeda Philippines

Arabella Benedito - [email protected]

COMCO Southeast Asia

Ferdinand Bondoy - [email protected]

Joyce Yu - [email protected]

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”,

“hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.